Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients

Transforming growth factor β‐mediated micromechanics modulates disease progression in primary myelofibrosis

“…We indeed showed that micromechanics is altered in the bone marrow, not bringing forward any evidence for the same process occurring in the lung tissue. Still, clinical data have shown that PMF patients do indeed experience pulmonary hypertension, [56][57][58] as did our patient cohort, according to international echocardiography guidelines. [59] When assessing pulmonary hypertension in PMF patients, we used a small cohort as a proof-of-concept preliminary study.…”

Association of Disease Subtype and Duration with Echocardiographic Evidence of Pulmonary Hypertension in Myeloproliferative Neoplasm

“…Similarly, in another report, the prevalence of PH was found to be almost 5% and the mean time since the diagnosis of MPNs was about 15 months [10]. Recently, Venton et al [11] reported a slightly higher prevalence of 7.7% with a median follow-up of 46.5 months and the presence of primary myelofibrosis as the main cause. In our study, disease duration was much higher than theirs (6.7 years); however, due to the cross-sectional design of our study, it is not possible to confirm the exact time when our patients developed PH.…”

Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients

“…All studies reported to date were retrospective in nature. In addition, majority of recent studies analyzed 20–50% candidates [ 23 - 26 ], and thus, may not have been representative of the entire patient population, leading to selection bias. In our study, 70% Ph - MPN patients underwent TTE, and the characteristics and clinical features of these patients did not differ significantly from the whole patient population.…”

“…Therefore, they concluded that screening for PH is not necessary in MPN patients. A French study reported 14 (7.7%) cases of primary PH among 183 MPN patients, including 28 with CML [ 23 ]. In contrast, two American studies reported high PH prevalence rates of >50% [ 25 , 26 ].…”

“…However, these conclusions have been drawn primarily on the basis of early case reports and small case series with highly variable prevalence rates (5-50%) [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]. Recently, some studies including larger cohorts of MPN patients have been reported; however, the prevalence of PH varied markedly among these studies [23][24][25][26]. Furthermore, no studies have yet included the Asian populations.…”